The central theme of Research Project 3 {RP3) is biologic discovery with selective targeted inhibitors of the two signal transduction pathways that are activated most frequently in human cancer: RAS/RAF/ERK and PI3K/AKT/MT0R. Multiple inhibitors of RAF, MEK, P13K, AKT, and mTor are now being developed for the treatment of these tumors. In this proposal. Molecular Imaging (Ml) with PET and MRI w/ill be used as a guide for understanding target inhibition and optimizing these therapeutic regimens. This work is based on recent fundamental studies from our group on pathway regulation and function;effects of inhibitors on components of these pathway;development of Ml modalities for imaging pathway inhibition and tumor response in preclinical models and patients. The recent clinical trial of the RAF inhibitor PLX4032 in melanomas with mutant BRAF was based in large part on our basic findings and resulted in an 85% clinical response rate and serves as proof of principle for the utility of targeting these pathways (NEJM 2010;363:809-19). ERK signaling drives the proliferation of tumors in which it is activated and we have shown that inhibition of the pathway can be imaged effectively with by FLT/PET (Cancer Res. 2007;67:11463-9), In contrast, PI3K/AKT/mTor signaling regulates glucose homeostasis and FDG uptake is very sensitive to mTor inhibitors. These data suggest a role for Ml both as a measure of pharmacodynamic pathway inhibition and tumor response, as well as other changes in tumor biology. For instance, in recent trials, we showed that ERK pathway inhibition induces the iodide transporter and iodine avidity of tumors with mutant BFIAF. The RPS research plan is comprised of the fallowing specific aims. SAl;.Imaging the effects of selective inhibition of P13K signaling in tumors with mutational activation of the pathway. SA2: Imaging the effects of selective inhibition of ERK signaling in tumors with mutant BRAF. SA3: Imaging the effects of combination therapy utilizing inhibitors of P13K or ERK signaling. The major goal of the project is to develop imaging as a tool for measuring the quantitative and temporal effects of targeted drugs on pathway inhibition, tumor biology and tumor growth. The inhibitors we are using are all in or about to enter trials, the major limitations of which are the inability to assess pathway inhibition or to rationally choose combinations, so we expect the findings in this project to be rapidly translated and to have a major clinical impact.

Public Health Relevance

Malignant melanoma, thyroid cancer, colon cancer and breast cancers are known to harbor mutations to key molecules that change a normal cell to a cancerous one. Recently, special drugs which disable only the mutated, cancer-producing molecules have been discovered, and early clinical results are promising. Only a portion of patients respond, and duration of treatment response is relatively short. Molecular imaging after treatment with selective drugs will be used to improve duration of response and chances of cure.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA086438-13
Application #
8567121
Study Section
Special Emphasis Panel (ZCA1-SRLB-9)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
13
Fiscal Year
2013
Total Cost
$237,286
Indirect Cost
$107,390
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Rodina, Anna; Wang, Tai; Yan, Pengrong et al. (2016) The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature 538:397-401
Lee, Sang-Gyu; Gangangari, Kishore; Kalidindi, Teja Muralidhar et al. (2016) Copper-64 labeled liposomes for imaging bone marrow. Nucl Med Biol 43:781-787
Demoin, Dustin Wayne; Shindo, Masahiro; Zhang, Hanwen et al. (2016) Synthesis and evaluation of an (18)F-labeled pyrimidine-pyridine amine for targeting CXCR4 receptors in gliomas. Nucl Med Biol 43:606-11
Arevalo-Perez, Julio; Paris, Manuel; Graham, Michael M et al. (2016) A Perspective of the Future of Nuclear Medicine Training and Certification. Semin Nucl Med 46:88-96
Cheal, Sarah M; Xu, Hong; Guo, Hong-Fen et al. (2016) Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. Eur J Nucl Med Mol Imaging 43:925-37
Wang, Xiuyan; Rivière, Isabelle (2016) Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics 3:16015
Cherkassky, Leonid; Morello, Aurore; Villena-Vargas, Jonathan et al. (2016) Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest 126:3130-44
Kadota, Kyuichi; Sima, Camelia S; Arcila, Maria E et al. (2016) KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma. Am J Surg Pathol 40:1579-1590
Mayor, Marissa; Yang, Neng; Sterman, Daniel et al. (2016) Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg 49:1324-33
Adusumilli, Prasad S (2016) Spread through alveolar spaces: An aerogenous invasion in pulmonary adenocarcinomas. J Thorac Cardiovasc Surg 152:73-4

Showing the most recent 10 out of 177 publications